Artiva Biotherapeutics, Inc. Variable Lease, Cost
Artiva Biotherapeutics, Inc. (ARTV) reported Variable Lease, Cost of $345.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. variable lease, cost for the quarter ending 2026-06-30 was $345.00K, a 37.50% decline year-over-year.
- Artiva Biotherapeutics, Inc. variable lease, cost for the quarter ending 2026-03-31 was $356.00K, a 26.29% decline year-over-year.
- Artiva Biotherapeutics, Inc. variable lease, cost for the quarter ending 2025-12-31 was $562.00K, a 11.51% increase year-over-year.
- Artiva Biotherapeutics, Inc. variable lease, cost for the quarter ending 2025-09-30 was $552.00K, a 7.81% increase year-over-year.
- Artiva Biotherapeutics, Inc. variable lease, cost for fiscal 2025 was $2.15M, a 5.91% increase from fiscal 2024.
- Artiva Biotherapeutics, Inc. variable lease, cost for fiscal 2024 was $2.03M, a 12.88% decline from fiscal 2023.
- Artiva Biotherapeutics, Inc. variable lease, cost for fiscal 2023 was $2.33M.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $345.00K 10-Q · filed 2026-08-06 | $701.00K 10-Q · filed 2026-08-06 | $1.26M derived: sum of 3 quarters · filed 2026-08-06 | $1.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $356.00K 10-Q · filed 2026-05-08 | $918.00K derived: sum of 2 quarters · filed 2026-05-08 | $1.47M derived: sum of 3 quarters · filed 2026-05-08 | $2.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $562.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $1.11M derived: sum of 2 quarters · filed 2026-03-10 | $1.67M derived: sum of 3 quarters · filed 2026-08-06 | $2.15M 10-K · filed 2026-03-10 |
| 2025-09-30 | $552.00K 10-Q · filed 2025-11-12 | $1.10M derived: sum of 2 quarters · filed 2026-08-06 | $1.59M 10-Q · filed 2025-11-12 | $2.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $552.00K 10-Q · filed 2026-08-06 | $1.03M 10-Q · filed 2026-08-06 | $1.54M derived: sum of 3 quarters · filed 2026-08-06 | $2.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $483.00K 10-Q · filed 2026-05-08 | $987.00K derived: sum of 2 quarters · filed 2026-05-08 | $1.50M derived: sum of 3 quarters · filed 2026-05-08 | $2.01M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $504.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $1.02M derived: sum of 2 quarters · filed 2026-03-10 | $1.52M derived: sum of 3 quarters · filed 2026-03-10 | $2.03M 10-K · filed 2026-03-10 |
| 2024-09-30 | $512.00K 10-Q · filed 2025-11-12 | $1.02M derived: sum of 2 quarters · filed 2025-11-12 | $1.52M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $507.00K 10-Q · filed 2025-08-06 | $1.01M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $507.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $2.33M 10-K · filed 2025-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |